Exhibit 99.1

	AutoImmune Inc.
	1199 Madia Street
	Pasadena, CA 91103
	Phone: 626-792-1235
	Fax: 626-792-1236

Contact:

Robert C. Bishop, Ph.D.

Chairman and Chief Executive Officer

AutoImmune Inc.

626-792-1235

website: http://www.autoimmuneinc.com

FOR IMMEDIATE RELEASE

AUTOIMMUNE INC. REPORTS 2008 FOURTH QUARTER AND YEAR END

FINANCIAL RESULTS

Pasadena, California, March 16, 2009 - AutoImmune Inc. (OTC BB: AIMM.OB) today reported a net loss of $129,000, or $0.01 per share basic and diluted, for the three months ended December 31, 2008, compared with a net loss of $56,000, or break even per share basic and diluted, for the three months ended December 31, 2007. For the year ended December 31, 2008, the net loss was $345,000, or $0.02 per share basic and diluted, compared with net loss of $118,000, or $0.01 per share basic and diluted for the same period in 2007. The primary reason for the increase in losses was the reduction in interest income due to lower market yields. As of December 31, 2008, the Company reported $8.5 million in cash and marketable securities as compared to $8.8 million in cash and marketable securities as of December 31, 2007.

Chairman of the Board and Chief Executive Officer Robert C. Bishop, Ph.D. stated, “Product sales at Colloral LLC, our joint venture with Deseret Laboratories, Inc., were up from the third quarter and from 2007. The response to marketing through our licensee, Bronson Laboratories, LLC is encouraging.” AutoImmune consolidates Colloral LLC for financial reporting purposes in accordance with FIN 46R “Consolidation of Variable Interest Entities.”

AutoImmune has exclusively licensed certain of its intellectual property rights to BioMS Medical Corp., a Canadian company. Under the license agreement, BioMS makes monthly diligence payments to AutoImmune and will pay royalties to AutoImmune on sales of its lead drug, dirucotide (formerly referred to as MBP8298), if it reaches the market. In December 2007, BioMS sublicensed its rights in this product to Eli Lilly and Company. The FDA has granted the product fast track designation. We expect final trial data will be available during the second half of 2009 from the first of two ongoing Phase III trials of dirucotide for the treatment of secondary progressive multiple sclerosis.

AutoImmune also announced today that its Annual Meeting of Shareholders will be held on Friday, May 22, 2009, at 11:00 a.m. EDT, at the offices of Nutter, McClennen & Fish, 155 Seaport Blvd. in Boston, Massachusetts. AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.

Statements in this release that are not strictly historical are forward-looking statements including statements about clinical trials and studies and future sales, royalties and revenue. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to the uncertainties of clinical trial results, the Company’s dependence on third parties for licensing revenue, and the risks of technological change and competition. These factors are more fully discussed, as are other factors, in the Company’s most recent Annual Report on Form 10-KSB filed with the Securities and Exchange Commission in the section entitled “Risk Factors.”

- Financial Chart Follows -

AUTOIMMUNE INC.

STATEMENT OF OPERATIONS

(Unaudited)

	Three months ended December 31,						Year ended December 31,
	2007			2008			2007			2008
Revenue	$	75,000		$	91,000		$	294,000		$	316,000
Costs and expenses:
Cost of revenue		1,000			16,000			21,000			45,000
Research and development		49,000			81,000			144,000			174,000
Selling, general and administrative		181,000			136,000			713,000			647,000
Total costs and expenses		231,000			233,000			878,000			866,000
Interest income		105,000			18,000			440,000			213,000
Minority interest in joint venture		(5,000	)		(5,000	)		1,000			(8,000	)
Other income		—			—			25,000			0
		100,000			13,000			466,000			205,000
Net loss	$	(56,000	)	$	(129,000	)	$	(118,000	)	$	(345,000	)
Net loss per share - basic	$	(0.00	)	$	(0.01	)	$	(0.01	)	$	(0.02	)
Net loss per share - diluted	$	(0.00	)	$	(0.01	)	$	(0.01	)	$	(0.02	)
Weighted average common shares outstanding - basic		16,979,623			16,999,623			16,970,558			16,999,022
Weighted average common shares outstanding - diluted		16,979,623			16,999,623			16,970,558			16,999,022

CONDENSED BALANCE SHEET

(Unaudited)

	December 31, 2007		December 31, 2008
Cash and marketable securities	$	8,804,000	$	8,475,000
Other current assets		167,000		195,000
Total assets	$	8,971,000	$	8,670,000
Current liabilities	$	128,000	$	147,000
Minority interest in joint venture		11,000		33,000
Total stockholders’ equity		8,832,000		8,490,000
Total liabilities and equity	$	8,971,000	$	8,670,000